Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Jun 2, 2026

Sana Biotechnology to Present at June 2026 Investor Conferences

SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.

GlobeNewsWire • May 27, 2026

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company's common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined with the previously announced unrelated $25 million investment from the Mayo Clinic, brings the total capital raised since the end of the first quarter of 2026 to approximately $94 million and extends the company's expected cash runway to mid-2027.

GlobeNewsWire • May 15, 2026

Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates (NHPs) without the use of lymphodepleting chemotherapy. SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells.

GlobeNewsWire • May 12, 2026

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451

GlobeNewsWire • May 11, 2026

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m. PT on Tuesday, May 12, 2026.

GlobeNewsWire • May 5, 2026

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.

GlobeNewsWire • Apr 27, 2026

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Seeking Alpha • Mar 18, 2026